High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients
(1) Background: Individuals carrying a pathogenic transthyretin gene variant (<i>TTRv</i>) are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM). This study aims to evaluate whether the car...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/3/810 |
| _version_ | 1797318545318608896 |
|---|---|
| author | Hendrea S. A. Tingen Milou Berends Alwin Tubben Johan Bijzet Ewout J. Houwerzijl Friso L. H. Muntinghe Bart-Jan Kroesen Paul A. van der Zwaag Peter van der Meer Riemer H. J. A. Slart Bouke P. C. Hazenberg Hans L. A. Nienhuis |
| author_facet | Hendrea S. A. Tingen Milou Berends Alwin Tubben Johan Bijzet Ewout J. Houwerzijl Friso L. H. Muntinghe Bart-Jan Kroesen Paul A. van der Zwaag Peter van der Meer Riemer H. J. A. Slart Bouke P. C. Hazenberg Hans L. A. Nienhuis |
| author_sort | Hendrea S. A. Tingen |
| collection | DOAJ |
| description | (1) Background: Individuals carrying a pathogenic transthyretin gene variant (<i>TTRv</i>) are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM). This study aims to evaluate whether the cardiac biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) can be used to rule out ATTRv-CM. (2) Methods: In this retrospective case-control study, data from 46 ATTRv-CM patients and 101 <i>TTRv</i> carriers and ATTRv amyloidosis patients without cardiomyopathy were included. Binary logistic regression models were used to assess the ability of NT-proBNP and hs-cTnT to predict the diagnosis of ATTRv-CM. An optimal cutoff for the relevant biomarker(s) was determined based on a sensitivity of ≥99% and the highest possible percentage of additional tests avoided (%ATA) in the index dataset. (3) Results: Hs-cTnT demonstrated the highest predictive capabilities for ATTRv-CM. The addition of NT-proBNP did not improve the predictive model. A hs-cTnT cutoff of <6 ng/L resulted in a 97% sensitivity and a negative predictive value of 95% with a %ATA of 30% in the validation dataset. (4) Conclusion: In conclusion, hs-cTnT is a useful biomarker for excluding cardiac involvement in <i>TTRv</i> carriers and ATTRv amyloidosis patients and it has the potential to prevent unnecessary diagnostic procedures. |
| first_indexed | 2024-03-08T03:53:59Z |
| format | Article |
| id | doaj.art-b7a510cdd8254c81842eb8c6bd9c76a2 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T03:53:59Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-b7a510cdd8254c81842eb8c6bd9c76a22024-02-09T15:16:10ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113381010.3390/jcm13030810High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis PatientsHendrea S. A. Tingen0Milou Berends1Alwin Tubben2Johan Bijzet3Ewout J. Houwerzijl4Friso L. H. Muntinghe5Bart-Jan Kroesen6Paul A. van der Zwaag7Peter van der Meer8Riemer H. J. A. Slart9Bouke P. C. Hazenberg10Hans L. A. Nienhuis11Department of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Cardiology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Laboratory Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Laboratory Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Genetics, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Cardiology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Rheumatology & Clinical Immunology, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The NetherlandsDepartment of Internal Medicine, Groningen Amyloidosis Centre of Expertise, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands(1) Background: Individuals carrying a pathogenic transthyretin gene variant (<i>TTRv</i>) are at high risk for developing hereditary transthyretin (ATTRv) amyloidosis and are routinely screened for the development of cardiomyopathy (ATTRv-CM). This study aims to evaluate whether the cardiac biomarkers N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) can be used to rule out ATTRv-CM. (2) Methods: In this retrospective case-control study, data from 46 ATTRv-CM patients and 101 <i>TTRv</i> carriers and ATTRv amyloidosis patients without cardiomyopathy were included. Binary logistic regression models were used to assess the ability of NT-proBNP and hs-cTnT to predict the diagnosis of ATTRv-CM. An optimal cutoff for the relevant biomarker(s) was determined based on a sensitivity of ≥99% and the highest possible percentage of additional tests avoided (%ATA) in the index dataset. (3) Results: Hs-cTnT demonstrated the highest predictive capabilities for ATTRv-CM. The addition of NT-proBNP did not improve the predictive model. A hs-cTnT cutoff of <6 ng/L resulted in a 97% sensitivity and a negative predictive value of 95% with a %ATA of 30% in the validation dataset. (4) Conclusion: In conclusion, hs-cTnT is a useful biomarker for excluding cardiac involvement in <i>TTRv</i> carriers and ATTRv amyloidosis patients and it has the potential to prevent unnecessary diagnostic procedures.https://www.mdpi.com/2077-0383/13/3/810amyloidosistransthyretinATTRvcardiaccardiomyopathycarriers |
| spellingShingle | Hendrea S. A. Tingen Milou Berends Alwin Tubben Johan Bijzet Ewout J. Houwerzijl Friso L. H. Muntinghe Bart-Jan Kroesen Paul A. van der Zwaag Peter van der Meer Riemer H. J. A. Slart Bouke P. C. Hazenberg Hans L. A. Nienhuis High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients Journal of Clinical Medicine amyloidosis transthyretin ATTRv cardiac cardiomyopathy carriers |
| title | High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients |
| title_full | High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients |
| title_fullStr | High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients |
| title_full_unstemmed | High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients |
| title_short | High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients |
| title_sort | high sensitivity cardiac troponin t to exclude cardiac involvement in ttr variant carriers and attrv amyloidosis patients |
| topic | amyloidosis transthyretin ATTRv cardiac cardiomyopathy carriers |
| url | https://www.mdpi.com/2077-0383/13/3/810 |
| work_keys_str_mv | AT hendreasatingen highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT milouberends highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT alwintubben highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT johanbijzet highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT ewoutjhouwerzijl highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT frisolhmuntinghe highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT bartjankroesen highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT paulavanderzwaag highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT petervandermeer highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT riemerhjaslart highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT boukepchazenberg highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients AT hanslanienhuis highsensitivitycardiactroponinttoexcludecardiacinvolvementinttrvariantcarriersandattrvamyloidosispatients |